|Title:|| Method of producing analgesia|
|Abstract:||A method of producing analgesia and enhancing opiate analgesia is disclosed. The method includes administering TVIA (SNX-185) or MVIIA (SNX-111) omega-conopeptide, or derivative thereof which is characterized by its ability to (a) inhibit voltage-gated calcium channels selectively in neuronal tissue, as evidenced by the peptide's ability to inhibit electrically stimulated contraction of the guinea pig ileum, and (b) bind to omega-conopeptide MVIIA binding sites present in neuronal tissue.|
|Inventor(s):|| Justice; Alan (Sunnyvale, CA), Singh; Tejinder (Palo Alto, CA), Gohil; Kishor C. (Richmond, CA), Valentino; Karen L. (San Carlos, CA) |
|Assignee:|| Neurex Corporation (Menlo Park, CA) |
1. A method of producing analgesia in a mammalian subject, comprising
administering to the subject, in the absence of an opiate, an omega conopeptide selected from the group consisting of TVIA (SNX-185), MVIIA (SNX-111) and derivatives thereof, wherein said omega conopeptide is effective (a) to inhibit electrically
stimulated contraction of the guinea pig ileum, and (b) to bind selectively to omega conopeptide MVIIA binding sites present in neuronal tissue.
2. The method of claim 1, wherein the activities of the omega-conopeptide in calcium channel inhibition and in binding to the MVIIA binding site are within the ranges of such activities of omega-conopeptides MVIIA and TVIA.
3. The method of claim 1, wherein the omega-conopeptide is MVIIA or TVIA.
4. The method of claim 1, wherein the omega-conopeptide is administered intrathecally.